Cipla Steps Into Regenerative Medicine With Ciplostem Knee OA Therapy

Ciplostem, launched today by Cipla in partnership with Stempeutics Research, signals a strong move into orthobiologic medicine.

The new MSC therapy enters the market as India faces a fast-growing burden of knee osteoarthritis, now affecting more than 48.4 million people.

Many patients rely on painkillers and physiotherapy, which offer only short-lived relief and do little to slow joint damage.

Approved by the Drug Controller General of India, Ciplostem introduces an off-the-shelf, allogeneic treatment approach. Because the cells come from a donor rather than the patient, the therapy is ready for use without the wait of personalized preparation. This single-dose injection delivers 25 million cultured adult bone marrow–derived mesenchymal stromal cells, paired with hyaluronic acid, directly into the affected knee.

Also Read: Navigating the New Era of Nitrosamine Compliance

The Treatment is used for Grade II & III (knee OA) on the basis of its ability to reduce Inflammation, relieve Pain, and help maintain Cartilage at a Cellular Level. Therefore, this treatment would represent a Significant Transition from Symptomatic Therapies to Regenerative Therapies, to allow Providers and the Overall Industry, to focus on disease progression as opposed to just addressing symptoms of the disease.

BN Manohar, MD and CEO of Stempeutics Research, emphasized the scientific depth behind the therapy, stating: “Ciplostem sets a new benchmark in regenerative medicine, reflecting years of dedicated research and robust Phase 3 evidence. We are pleased to partner with Cipla to extend the reach of this stem cell therapy in India, transforming scientific innovation into tangible patient impact.”

With this launch, Cipla positions Ciplostem as a high-value entrant in a market eager for advanced, long-acting treatment options for knee osteoarthritis.